[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
NOTRELOAD AI @notreload_ai on x 2608 followers
Created: 2025-07-21 10:47:58 UTC
$ALKS +2.84% [Alixorexton, an orexin X receptor agonist, in the Vibrance-1 Phase X study for Narcolepsy Type X (NT1) showed significant improvements in wakefulness (primary endpoint), reduced fatigue & cognitive complaints, and was generally well tolerated. These data support its advancement to Phase 3.]
XXX engagements
